Broadly neutralizing antibodies (bNAbs) target conserved HIV envelope regions to neutralize diverse strains, eliminate infected cells and reduce viral reservoirs, complementing antiretroviral therapy and supporting prevention and functional cure strategies.
Researchers from Synklino A/S have published preclinical data supporting the potential of SYN-002, a targeted antiviral therapy that eliminates human cytomegalovirus (HCMV)‑infected cells by specifically targeting US28, a CMV‑encoded receptor expressed during infection.
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral therapy. At the Conference on Retroviruses and Opportunistic Infections (CROI) held Feb. 22-25, 2026, in Denver, the scientific community examined how the virus affects the brain, how the reservoir is established in the CNS, and which genetic, immunological or treatment-related factors influence cognitive health.
Researchers from Model Medicines Inc. have presented preclinical efficacy data for MDL-001, a first-in-class, oral non-nucleoside inhibitor that targets an allosteric site in the Thumb-1 domain of the viral polymerase.
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many of them are aging in good health. However, others present symptoms of cognitive decline. HIV can reach the brain and establish a reservoir there. Yet, it is still unknown what this reservoir is like, which cells are affected, and which comorbidities are typical of aging or are associated with the virus.
Centauri Therapeutics Ltd. has extended its series A financing round to £30 million (US$40.5 million) with the addition of a new £6 million (US$8 million) investment. Centauri initially closed its £24 million (US$32 million) series A round in 2022.
Researchers from the University of Sassari (Italy) and their collaborators have recently published findings from their research focused on the impact of one allelic variant in the CCND3 gene, encoding cyclin D3, on blood cell traits and resistance to malaria.
Stoked Bio Inc. has secured an exclusive global license from McMaster University for the patents covering enterololin, a promising narrow-spectrum antibiotic.
Antimicrobial resistance (AMR) is increasingly compromising the effectiveness of essential antibiotics, resulting in higher global mortality and morbidity rates. Despite this urgent need, few new antibiotics, particularly against gram-negative bacteria, are in development.
Chikungunya virus is a positive-sense single-stranded RNA virus for which no antiviral therapy has been approved. Nucleotide analogues are among the most promising broad-spectrum antivirals, as they inhibit viral RNA-dependent RNA polymerase, an essential enzyme for RNA virus replication.
RSS
